Pacira BioSciences
PCRX
270 hedge funds and large institutions have $3.49B invested in Pacira BioSciences in 2021 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 82 increasing their positions, 103 reducing their positions, and 23 closing their positions.
123% more call options, than puts
Call options by funds: $9.92M | Put options by funds: $4.45M
52% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 23
16% more capital invested
Capital invested by funds: $3.01B → $3.49B (+$477M)
4% more funds holding
Funds holding: 260 → 270 (+10)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.3% less ownership
Funds ownership: 115.94% → 113.64% (-2.3%)
20% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 103
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$38.4M |
| 2 |
LCG
Lisanti Capital Growth
New York
|
+$13.1M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$12.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.95M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$9.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$28.6M |
| 2 |
Renaissance Technologies
New York
|
-$22.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$21.9M |
| 4 |
D.E. Shaw & Co
New York
|
-$18.5M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$15.3M |
PCRX Hedge Fund Activity: Q1 2021 in Review
270 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2021, worth a combined $3.49B — up 16% from $3.01B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new PCRX positions and 23 closed out — a net gain of 12 holders — while 82 added to existing stakes and 103 trimmed.
The largest buyer was Macquarie Group, adding an estimated $38.4M. The largest seller was Westfield Capital Management, cutting an estimated $28.6M.
- 270 institutional investors held Pacira BioSciences (PCRX) as of Q1 2021, up from 260 in Q4 2020.
- Funds reported $3.49B of Pacira BioSciences stock for Q1 2021, up 16% quarter-over-quarter.
- 35 funds opened new Pacira BioSciences positions in Q1 2021 and 23 closed out, a net change of +12 holders.
- The largest Pacira BioSciences buyer in Q1 2021 was Macquarie Group, an estimated $38.4M added.
- The largest Pacira BioSciences seller in Q1 2021 was Westfield Capital Management, an estimated $28.6M sold.
Based on aggregated 13F filings for Q1 2021.